Skip to main content
OpenTrials
Completed

NCT Number: NCT03610256

Single-anastomosis Duodeno Ileal Bypass (SADI) Versus Roux-en-Y Gastric Bypass

Obesity is a major public health problem worldwide. Bariatric surgery has proved to be the most effective treatment of morbid obesity in terms of weight reduction and remission of co-morbid conditions during long-term follow-up. Nowadays, France is ranked 3rd in terms of bariatric surgeries performed per year.

Since the laparoscopic Roux-en-Y gastric bypass (RYGB) was described in 1977, this restrictive and malabsorptive procedure has become a gold standard for morbid obesity with an average Excess Weight Loss % (EWL%) of 72% at 2 years, and a strong metabolic effect, especially with regard to type 2 diabetes remission. Nevertheless, failures are observed (up to 20%), particularly in super obese patients, which are then difficult to manage. In this population, biliopancreatic diversion with duodenal switch (BPD-DS) is indicated due to its stronger weight loss and metabolic effect, but is still little performed worldwide because of its higher morbidity, surgical complexity and risk of malnutrition.

A novel technique combining the physiological advantages of pylorus preservation and the technical benefits of single-loop reconstruction was introduced in 2007 by Sanchez-Pernaute, who described the single-anastomosis duodeno-ileal bypass with sleeve gastrectomy (SADI-S) as an evolution of the BPD-DS. With a 2.5-meter common channel, SADI-S seems to offer good results for the treatment of both morbid obesity and its metabolic complications, with an EWL% of up to 95% at 2 years and potentially less nutritional consequences.

To date, there is only one Spanish randomized trial comparing SADI-S to BPD-DS, whereas BPD-DS represents less than 1% of bariatric procedures in France and is only allowed in super obese patients. Thus only preliminary data of poor scientific value exists. Nevertheless, facing very encouraging short-term outcomes, there is a real need for a prospective trial comparing SADI-S to a standard bariatric procedure.

The aim of the investigator's study is to assess weight loss efficiency and the morbi-mortality of the SADI-S in comparison to a standard (RYGB), in order to validate this procedure among bariatric techniques

HYPOTHESIS SADI-S is superior to the standard RYGB for weight loss, increasing the EWL% by 10% (82% vs 72%, respectively) at 2 years.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Obesity, Morbid Body Weight Nutrition Disorders Nutritional and Metabolic Diseases Obesity Overnutrition Overweight Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Département de Chirurgie Digestive et Viscérale - Clinique de l'Anjou, Angers, France

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient aged between 18 and 65 years old,
  • Morbid obesity with BMI ≥40 kg/m2 or BMI ≥35 kg/m2 associated with one co-morbidity which will be improved by surgery (high blood pressure, type 2 diabetes mellitus, obstructive sleep apnea, dyslipidemia, arthrosis)
  • Patient who has benefited from an upper GI endoscopy with biopsies to look for Helicobacter pylori , within the 12 months before surgery,
  • Patient who has benefited from a pluridisciplinary evaluation, with a favorable opinion for SADI-S or RYGB as a primary surgery or after failure of sleeve gastrectomy (defined as insufficient weight loss at 18 months after surgery (EWL% <50), or as weight regain (+ 20%)).
  • Patient who understands and accepts the need for a long term follow-up,
  • Patient who agrees to be included in the study and who signs the informed consent form,
  • Patient affiliated with a healthcare insurance plan.

Exclusion criteria

  • History of previous bariatric surgery, other than a sleeve gastrectomy,
  • Presence of a severe and evolutive life threatening pathology, unrelated to obesity,
  • History of type 1 diabete,
  • History of chronic inflammatory bowel disease,
  • Pregnancy or desire to be pregnant during the study,
  • Presence of Helicobacter pylori resistant to medical treatment,
  • Presence of a unhealed gastro-duodenal ulcer or diagnosed less than 2 months previously,
  • Mentally unbalanced patients, under supervision or guardianship,
  • Patient who does not understand French/ is unable to give consent,
  • Patient not affiliated to a French or European healthcare insurance,
  • Patient who has already been included in a trial which has a conflict of interests with the present study

Treatment and study plan

SADI-S

Procedure

Laparoscopic SADI-S, recently described as an evolution of the BPD-DS, combining the physiological advantages of pylorus preservation and the technical benefits of single-loop reconstruction, associating a sleeve gastrectomy and a duodeno-ileal bypass at 2.5 meters from the ileo-caecal valve if BMI ≥ 50 kg/m² or at 3 meters if BMI < 50

Other names: Laparoscopic Single-anastomosis duodeno ileal bypass with Sleeve gastrectomy (SADI-S)

RYGB

Procedure

The laparoscopic Roux-en-Y Gastric Bypass will consist of:

  • a small gastric pouch (about 30cc)
  • an antecolic alimentary limb
  • a gastro-jejunal anastomosis using a linear stapler
  • a 150cm long alimentary limb
  • a 50cm biliary limb
  • a latero-lateral jejuno-jejunal anastomosis
  • closure of the mesenteric defects

Other names: Roux-en-Y Gastric ByPass

Primary outcomes

  1. Excess Weight Loss measurement

    Time frame: 2 years after surgery

    For each surgical procedure, weight loss will be assessed 2 years after surgery using Excess Weight Loss percentage (EWL%), calculated using the following formula:

    ((weight at 2-year visit - initial weight) / (initial weight - ideal weight)) X 100 The assessment of the primary endpoint will be standardized between the centers and carried out under blind conditions.

Secondary outcomes

  1. Albumin

    Time frame: At each study visit (before surgery and 1, 3, 6, 12,18, 24, 60 and 120 months after surgery)

    Measurement of albumin will explore the nutritional status of patients. Results will be expressed in g/l

  2. Pre-albumin

    Time frame: At each study visit (before surgery and 1, 3, 6, 12,18, 24, 60 and 120 months after surgery)

    Measurement of pre-albumin will explore the nutritional status of patients. Results will be expressed in g/l

  3. Hemoglobin

    Time frame: At each study visit (before surgery and 1, 3, 6, 12,18, 24, 60 and 120 months after surgery)

    Measurement of Hemoglobin will explore the nutritional status of patients. Results will be expressed in g/l

  4. Calcium

    Time frame: At each study visit (before surgery and 1, 3, 6, 12,18, 24, 60 and 120 months after surgery)

    Measurement of Calcium will explore the nutritional status of patients. Results will be expressed in mmol/l

  5. Ferritin

    Time frame: At each study visit (before surgey and 1, 3, 6, 12,18, 24, 60 and 120 months after surgery)

    Measurement of ferritin will explore the nutritional status of patients. Results will be expressed in microg/l

  6. Iron

    Time frame: At each study visit (before surgery and 1, 3, 6, 12,18, 24, 60 and 120 months after surgery)

    Measurement of iron will explore the nutritional status of patients. Results will be expressed in micromol/l

  7. % of transferrin saturation

    Time frame: At each study visit (before surgery and 1, 3, 6, 12,18, 24, 60 and 120 months after surgery)

    Measurement of % of transferrin saturation will explore the nutritional status of patients. Results will be expressed in %

  8. Vitamin A

    Time frame: Before surgery and 6, 12, 24, 60 and 120 months after surgery

    Measurement of vitamin A will explore the nutritional status of patients. Results will be expressed in micromol/l

  9. Vitamin B1

    Time frame: Before surgery and 6, 12, 24, 60 and 120 months after surgery

    Measurement of vitamin B1 will explore the nutritional status of patients. Results will be expressed in nmol/l

  10. Vitamin B12

    Time frame: Before surgery and 6, 12, 24, 60 and 120 months after surgery

    Measurement of vitamin B12 will explore the nutritional status of patients. Results will be expressed in pmol/l

  11. Vitamin B9

    Time frame: Before surgery and 6, 12, 24, 60 and 120 months after surgery

    Measurement of vitamin B9 will explore the nutritional status of patients. Results will be expressed in nmol/l

  12. Vitamin D

    Time frame: Before surgery and 6, 12, 24, 60 and 120 months after surgery

    Measurement of vitamin D will explore the nutritional status of patients. Results will be expressed in nmol/l

  13. Vitamin C

    Time frame: Before surgery and 6, 12, 24, 60 and 120 months after surgery

    Measurement of vitamin C will explore the nutritional status of patients. Results will be expressed in micromol/l

  14. Vitamin E

    Time frame: Before surgery and 6, 12, 24, 60 and 120 months after surgery

    Measurement of vitamin E will explore the nutritional status of patients. Results will be expressed in micromol/l

  15. Prothrombin rate

    Time frame: Before surgery and 6, 12, 24, 60 and 120 months after surgery

    Measurement of prothrombine rate will explore the nutritional status of patients. Results will be expressed in %

  16. Steatorrhea rate

    Time frame: 6 month after surgery

    Measurement of the 24-hour steatorrhea rate will explore the nutritional status of patients. Results will be expressed in grams of lipids /100g of stools

  17. Average number of stools per day

    Time frame: At each study visit (before surgery and 1, 3, 6, 12,18, 24, 60 and 120 months after surgery)

    Measurement of the average number of stool will explore the nutritional status of patients. Results will be expressed in number of stool/day

  18. HbA1c

    Time frame: At each study visit (before surgery and 1, 3, 6, 12,18, 24, 60 and 120 months after surgery)

    Measurement of HbA1c will explore the Metabolic efficiency of surgery. Results will be expressed in %

  19. Fasting glycemia

    Time frame: At each study visit (before surgery and 1, 3, 6, 12,18, 24, 60 and 120 months after surgery)

    Measurement of fasting glycemia will explore the Metabolic efficiency of surgery. Results will be expressed in mmol/l

  20. HDL

    Time frame: At each study visit (before surgery and 1, 3, 6, 12,18, 24, 60 and 120 months after surgery)

    Measurement of HDL will explore the Metabolic efficiency of surgery. Results will be expressed in mmol/l

  21. LDL

    Time frame: At each study visit (before surgery and 1, 3, 6, 12,18, 24, 60 and 120 months after surgery)

    Measurement of LDL will explore the Metabolic efficiency of surgery. Results will be expressed in mmol/l

  22. Cholesterol

    Time frame: At each study visit (before surgery and 1, 3, 6, 12,18, 24, 60 and 120 months after surgery)

    Measurement of cholesterol will explore the Metabolic efficiency of surgery. Results will be expressed in mmol/l

  23. Triglycerides

    Time frame: At each study visit (before surgery and 1, 3, 6, 12,18, 24, 60 and 120 months after surgery)

    Measurement of triglycerides will explore the Metabolic of surgery. Results will be expressed in mmol/l

  24. Antidiabetic drugs

    Time frame: Before surgery and 6, 12, 24, 60 and 120 months after surgery

    Evolution of antidiabetic drugs will explore the Metabolic efficiency of surgery. This outcome will be expressed in terms of increase, decrease, discontinuation or restart of treatment.

  25. Antilipidemic drugs

    Time frame: Before surgery and 6, 12, 24, 60 and 120 months after surgery

    Evolution of antilipidemic drugs will explore the Metabolic efficiency of surgery. This outcome will be expressed in terms of increase, decrease, discontinuation or restart of treatment.

  26. Antihypertensive drugs

    Time frame: Before surgery and 6, 12, 24, 60 and 120 months after surgery

    Evolution of antihypertensive drugs will explore the Metabolic efficiency of surgery. This outcome will be expressed in terms of increase, decrease, discontinuation or restart of treatment.

  27. Use of Continuous Positive Airway Pressure for Obstructive Sleep Apnea

    Time frame: Before surgery and 6, 12, 24, 60 and 120 months after surgery

    Evolution of the use of Continuous Positive Airway Pressure for Obstructive Sleep Apnea will explore the Metabolic efficiency of surgery. This outcome will be expressed in terms of persistence or not of obstructive sleep apnea.

  28. Length of stay

    Time frame: End of the hospitalization period

    The Length of stay (in days) is based on the number of days of hospitalization from surgery (day of surgery = D0) until the end of hospitalization.

  29. Readmission of patient

    Time frame: 30 days after surgery

    Number of patients readmitted within 30 days after surgery.

  30. Occurrence of kidney stones

    Time frame: Within 10 years after surgery

    For each visit after the surgery, the presence or not of kidney stones will be documented and if applicable the treatment will be noted

  31. Overall complication rate

    Time frame: Within 10 years after surgery

    Rate of medical and surgical (> or = grade 3) complications within 120 months after surgery using the Dindo-Clavien classification, described as :

    Grade I = Any deviation from the normal postoperative course. Grade 2 = Requiring pharmacological treatment with drugs other than such allowed for grade I complications.

    Grade III = Requiring surgical, endoscopic or radiological intervention, not under (Grade IIIa) or under general anesthesia (Grade IIIb) Grade IV = Life-threatening complication with single organ (Grade IVa) or Multiorgan dysfunction (Grade IVb) Grade V = Death of a patient.

  32. Type and severity of early complications

    Time frame: Within 30 days after surgery

    Type (medical or surgical) and severity of early complications (within 30 days) for each procedure according to the Dindo-Clavien classification (description of this classification was made in outcome 32).

  33. Type and severity of late complications

    Time frame: Within 10 years after surgery

    Type (medical or surgical) and severity of late complications (after 30 days) for each procedure according to the Dindo-Clavien classification (description of this classification was made in outcome 32).

  34. Gastroesophageal reflux assessment

    Time frame: At each study visit (before surgery and 1, 3, 6, 12,18, 24, 60 and 120 months after surgery)

    Evolution of gastroesophageal reflux will be assessed at each study visit, before and after surgery. This outcome will be expressed in terms of improvement, aggravation or onset.

  35. Absolute weight loss assessment

    Time frame: 1, 3, 6, 12, 18, 24, 60 and 120 months after surgery

    Weight loss at 1, 3, 6, 12, 18, 24, 60 and 120 months after surgery, according to absolute weight loss (aWL) in kg.

  36. Excess Weight Loss percentage assessment

    Time frame: 1, 3, 6, 12, 18, 24, 60 and 120 months after surgery

    Weight loss at 1, 3, 6, 12, 18, 24, 60 and 120 months after surgery, according to Excess Weight Loss percentage (EWL%), calculated using the following formula:

    ((weight at visit X - initial weight) / (initial weight - ideal weight)) X 100

  37. Excess BMI Loss percentage assessment

    Time frame: 1, 3, 6, 12, 18, 24, 60 and 120 months after surgery

    Weight loss at 1, 3, 6, 12, 18, 24, 60 and 120 months after surgery, according Excess BMI Loss percentage (EBL%), according to the formula :

    ((BMI at visit X - initial BMI) / (initial BMI - ideal BMI)) X 100 with Ideal BMI = 25 kg/m²

  38. Quality of life assessed with GIQLI questionnaire

    Time frame: Before surgery and at 6, 12 and 24 months after surgery

    Before surgery and at 6, 12 and 24 months after surgery, according to the GIQLI questionnaire.

    This questionnaire consists of 36 items exploring 5 dimensions or subscales: symptoms, physical condition, emotions, social integration and the effect of any medical treatment. For each item, 5 responses will be proposed to the patients and for each answer, a score ranging from 0 to 4 (highest score = 144) will be assigned. A high score defines a more favorable health state.

  39. Quality of life assessed with SF36 questionnaire

    Time frame: Before surgery and at 6, 12 and 24 months after surgery

    Before surgery and at 6, 12 and 24 months after surgery, according to the SF36 questionnaire.

    This questionnaire taps eight health concepts: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/tiredness, and general health perceptions. It also includes a single item that provides an indication of a perceived change in health

  40. Quality of life assessed with Sigstad questionnaire

    Time frame: Before surgery and at 1, 3, 6, 12, 24, 60 and 120 months after surgery

    Sigstad questionnaire for all postoperative study visits (except 18 months after surgery).

    The Sigstad questionnaire allows the identification and diagnosis of postoperative dumping syndrome and early hypoglycaemia: a score >7 suggests a dumping syndrome

  41. Evolution of food choices and preferences within 2 years after surgery

    Time frame: Before surgery and 3, 12 and 24 months after surgery

    The evolution of food choices and preferences will be measured before surgery and 3, 12 and 24 months after surgery using a computerized test: the "Leeds Food Preference Questionnaire (LFPQ).

    The Leed Food Preference Questionnaire provides measurements of different components of food preference and food reward, and is a computerized questionnaire. Participants are presented with an array of pictures of individual food items common in the diet. Foods are chosen from a validated database to be either predominantly high (>50% energy) or low (<20% energy) in fat but similar in familiarity, protein content, sweet or not-sweet taste and palatability. Responses are recorded and used to compute mean scores for high fat, low fat, sweet or savory food types (and different fat-taste combinations).

    This assessment will be performed only in the coordinating center

  42. Modifications of the gastric and esophageal mucosa

    Time frame: 60 and 120 months after surgery

    Macroscopic data and Histological modifications of the gastric and esophageal mucosa based on upper GI endoscopy with biopsies of the gastric and esophageal mucosa

  43. Number of reflux episodes

    Time frame: 60 and 120 months after surgery

    Number of reflux episodes for assessment of severe GastroEsophageal Reflux Disease by pHmetry

  44. Number of reflux episodes lasting more than 5 minutes

    Time frame: 60 and 120 months after surgery

    Number of reflux episodes lasting more than 5 minutes for assessment of severe GastroEsophageal Reflux Disease by pHmetry

  45. Exposure time with pH < 4

    Time frame: 60 and 120 months after surgery

    % of exposure time with pH < 4 for assessment of severe GastroEsophageal Reflux Disease by pHmetry

  46. Number of acid refluxes

    Time frame: 60 and 120 months after surgery

    Number of acid refluxes for assessment of severe GastroEsophageal Reflux Disease by pH- impedancemetry

  47. Number of non-acid refluxes

    Time frame: 60 and 120 months after surgery

    Number of non-acid refluxes for assessment of severe GastroEsophageal Reflux Disease by pH- impedancemetry

  48. Number of poor acid reflux

    Time frame: 60 and 120 months after surgery

    Number of poor acid reflux for assessment of severe GastroEsophageal Reflux Disease by pH- impedancemetry

  49. Association with symptoms

    Time frame: 60 and 120 months after surgery

    Positive association with symptoms for assessment of severe GastroEsophageal Reflux Disease by pH- impedancemetry

Sponsors and collaborators

Lead sponsor

Hospices Civils de Lyon

Other

Registry information

Official study title

Prospective Multicentric Randomized Trial Comparing the Efficacy and Safety of Single-anastomosis Duodeno Ileal Bypass With Sleeve Gastrectomy (SADI-S) Versus Roux-en-Y Gastric Bypass (RYGB)

Acronym: SADISLEEVE

Important dates

Study start
2018
Primary completion
2023
Study completion
2023
First posted
Aug 1, 2018
Registry last updated
Sep 9, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.